Role of Adjunctive Intravitreal Therapy in Intraocular Tubercular Granuloma at a Tertiary Uveitis Care Centre - A Retrospective Case Series.

PURPOSE: To evaluate the role of intravitreal anti-VEGF with moxifloxacin in intraocular tubercular granuloma.

METHOD: This retrospective interventional study was conducted at a referral uveitis clinic between January 2022 and 2025. All patients who had received intravitreal anti-VEGF with moxifloxacin along with systemic anti-tubercular therapy (ATT) for intraocular tubercular (TB) granuloma were included.

RESULT: Ten eyes of ten consecutive patients with tubercular granulomas treated at our institution were analyzed. The median age of presentation was 32.5 years (range 18-44 years). The median duration of follow-up was 4 months (range 2-34 months).Seven cases had TB choroidal granuloma, two had ciliary body granuloma, and one had both choroidal and ciliary body granulomas. All patients received intravitreal anti-VEGF and moxifloxacin along with systemic ATT and oral steroids. Nine eyes had resolved granuloma till the last follow-up. One patient had persistent inflammation despite three intravitreal anti-VEGF injections along with moxifloxacin. The visual acuity improved in eight patients.

CONCLUSION: Adjunctive intravitreal therapy with anti-VEGF and moxifloxacin along with ATT aided in resolution of intraocular TB granuloma.